Can Long-Acting injections stop stimulant psychosis from worsening?
NCT ID NCT03485417
First seen Nov 15, 2025 · Last updated Jun 20, 2026 · Updated 25 times
Summary
This study tested two long-acting injectable medications, aripiprazole and paliperidone, in 165 people who use stimulants and have psychosis. The goal was to see if these drugs could better manage psychosis and prevent progression to chronic schizophrenia compared to standard treatment. Participants were randomly assigned to one of the two medications or to usual care, and their symptoms were tracked over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA AND RELATED DISORDERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Queen Mary Hospital
Hong Kong, 000000, Hong Kong
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aripiprazole and paliperidone (long-acting injectable forms)
What this could lead to
If successful, this could provide an evidence-based treatment strategy to better manage psychosis in people who use stimulants and reduce the risk of long-term dependence.
What could go wrong
This is a completed Phase 2/3 trial with 165 participants in Hong Kong, so results may not apply to other populations. The medications have side effects, and the study compares them to usual care, which may limit how broadly the findings can be used.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.